The ARO Platform of products are intended for the treatment of opioid use disorder and/or moderate-to-severe pain refractory to non-opioid therapy in patients in whom a state of enforced sobriety from alcohol is desired.
products in development
buprenorphine HCl-naloxone HCl-disulfiram
the way forward
SafeRx Pharmaceuticals is pursuing accelerated FDA approval of our ARO products through the 505(B)(2) regulatory pathway, which allows use of safety and efficacy studies already in the public domain.This means a much faster and less expensive route to approval.
To this end, we have partnered with Camargo Pharmaceutical Services, the 505(b)(2) pathway experts, and expect to achieve FDA approval of our inaugural ARO product, MethARO™ (methadone hydrochloride-disulfiram), by early 2024.